Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting

Krakow, Poland – 17 April 2019 – Selvita today announced that an abstract providing details of the Phase 1/2 study of SEL24/MEN1703 has been accepted as a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2019, in Chicago.


The abstract, entitled “CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia,” (Abstract #256995) will be presented by Farhad Ravandi-Kashani, M.D., of the University of Texas MD Anderson Cancer Center.


Additional information on the Phase 1/2 study, which is being conducted by Selvita’s partner Menarini Group, is available at



About Selvita

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways, and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.